Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Foundation Fighting Blindness funds gene therapy development
The grants will be allocated through the Foundation’s Translational Research Acceleration Program. One of the projects under the program involves the use of gene therapy to resurrect and
The grants will be allocated through the Foundation’s Translational Research Acceleration Program. One of the projects under the program involves the use of gene therapy to resurrect and
Oxo derivatives are used in automotive, construction, cosmetics, pharmaceutical and personal care products. The move is said to provide a boost to Oxea’s growth strategy in China. Oxea
As per the agreement, Mayo Clinic and Oxford BioMedica will take up clinical studies on glaucoma treatment using Oxford BioMedica’s LentiVector gene delivery technology. The technology expresses a
The European Commission (EC) has granted approval to Eli Lilly and Company for the use of Alimta (pemetrexed for injection) as a single agent for continuation maintenance therapy
Enoxaparin, a generic equivalent to Sanofi-aventis’ Lovenox is a low molecular weight heparin used to treat deep vein thrombosis and prophylaxis in unstable angina and non-Q-wave myocardial infarction.
The agreement comprises exclusive rights to manufacture, develop and commercialize the drug candidate across the globe, besides a joint Phase IIB/III clinical validation program. In addition, Atlab Pharma
Icagen is now part of Pfizer’s Worldwide Research and Development organization, and will be integrated into Neusentis, Pfizer’s Research Unit which includes Pain, Sensory Disorders and Regenerative Medicine.
The new software addresses health care center’s interoperability challenges by eliminating data connection barriers between Hospital Information Systems (HIS), physician EMR systems, patient care devices, Emergency Department Systems
The MAA includes Nuedexta phase 3 studies clinical data of in patients with PBA and also includes data from the company’s longer-term safety studies. Nuedexta comprises dextromethorphan hydrobromide
The MAA includes the efficacy and safety data of several studies involving over 4,000 patients, and also includes a long-term safety study with more than 600 patients. Dymista